Nair VD, Sealfon SC (2003) Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J Biol Chem 278, 47053-61 12970364

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S473-p - Akt1 (mouse) ▲

Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  SN4741 (neuron) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes bromocriptine increase

S473-p - Akt1 (rat) ▲

Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  PC-12 (chromaffin), SN4741 (neuron) Cellular systems studied:  cell lines Species studied:  mouse, rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase AG1478 EGF inhibit treatment-induced increase bromocriptine increase wortmannin bromocriptine inhibit treatment-induced increase LY294002 bromocriptine inhibit treatment-induced increase AG1478 bromocriptine inhibit treatment-induced increase PP2 bromocriptine inhibit treatment-induced increase PTX bromocriptine no effect upon treatment-induced increase H2O2 bromocriptine no effect upon treatment-induced increase pramipexole no change compared to control

Y870-p - EGFR (rat) ▲

Modsite: LGAEEKEyHAEGGKV SwissProt Entrez-Gene Orthologous residues EGFR (human): Y869‑p, EGFR iso2 (human): ‑, EGFR iso5 (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase bromocriptine increase PP2 bromocriptine inhibit treatment-induced increase AG1478 bromocriptine inhibit treatment-induced increase wortmannin bromocriptine no effect upon treatment-induced increase

Y1017-p - EGFR (rat) ▲

Modsite: DVVDADEyLIPQQGF SwissProt Entrez-Gene Orthologous residues EGFR (human): Y1016‑p, EGFR iso2 (human): ‑, EGFR iso5 (human): Y1016‑p, EGFR (mouse): Y1018‑p, EGFR (rat): Y1017‑p, EGFR (pig): Y1016‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase bromocriptine no change compared to control

Y1091-p - EGFR (rat) ▲

Modsite: TFLPVPEyINQSVPK SwissProt Entrez-Gene Orthologous residues EGFR (human): Y1092‑p, EGFR iso2 (human): ‑, EGFR iso5 (human): ‑, EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase bromocriptine no change compared to control

Y419-p - Src (rat) ▲

Modsite: RLIEDNEyTARQGAk SwissProt Entrez-Gene Orthologous residues Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y418‑p, Src iso1 (mouse): Y424‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  PC-12 (chromaffin) Cellular systems studied:  cell lines Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes bromocriptine increase PP2 bromocriptine inhibit treatment-induced increase AG1478 bromocriptine no effect upon treatment-induced increase wortmannin bromocriptine no effect upon treatment-induced increase